<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270024" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39377069</article-id><article-id pub-id-type="pmc">PMC11456614</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70024</article-id><article-id pub-id-type="publisher-id">DEO270024</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Endoscopic ultrasound&#x02010;guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study</article-title><alt-title alt-title-type="left-running-head">VANELLA <sc>et&#x000a0;al.</sc>
</alt-title></title-group><contrib-group><contrib id="deo270024-cr-0001" contrib-type="author" corresp="yes"><name><surname>Vanella</surname><given-names>Giuseppe</given-names></name><xref rid="deo270024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>vanella.giuseppe@hsr.it</email></address></contrib><contrib id="deo270024-cr-0002" contrib-type="author"><name><surname>Leone</surname><given-names>Roberto</given-names></name><xref rid="deo270024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270024-cr-0003" contrib-type="author"><name><surname>Frigo</surname><given-names>Francesco</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4503-4293</contrib-id><xref rid="deo270024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270024-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270024-cr-0004" contrib-type="author"><name><surname>Bronswijk</surname><given-names>Michiel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2039-5022</contrib-id><xref rid="deo270024-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="deo270024-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="deo270024-cr-0005" contrib-type="author"><name><surname>van Wanrooij</surname><given-names>Roy L. J.</given-names></name><xref rid="deo270024-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="deo270024-cr-0006" contrib-type="author"><name><surname>Tamburrino</surname><given-names>Domenico</given-names></name><xref rid="deo270024-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="deo270024-cr-0007" contrib-type="author"><name><surname>Orsi</surname><given-names>Giulia</given-names></name><xref rid="deo270024-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="deo270024-cr-0008" contrib-type="author"><name><surname>Belfiori</surname><given-names>Giulio</given-names></name><xref rid="deo270024-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="deo270024-cr-0009" contrib-type="author"><name><surname>Macchini</surname><given-names>Marina</given-names></name><xref rid="deo270024-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="deo270024-cr-0010" contrib-type="author"><name><surname>Reni</surname><given-names>Michele</given-names></name><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="deo270024-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="deo270024-cr-0011" contrib-type="author"><name><surname>Aldrighetti</surname><given-names>Luca</given-names></name><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="deo270024-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="deo270024-cr-0012" contrib-type="author"><name><surname>Falconi</surname><given-names>Massimo</given-names></name><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="deo270024-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="deo270024-cr-0013" contrib-type="author"><name><surname>Capurso</surname><given-names>Gabriele</given-names></name><xref rid="deo270024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270024-cr-0014" contrib-type="author"><name><surname>van der Merwe</surname><given-names>Schalk</given-names></name><xref rid="deo270024-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo270024-cr-0015" contrib-type="author"><name><surname>Arcidiacono</surname><given-names>Paolo Giorgio</given-names></name><xref rid="deo270024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="deo270024-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Pancreatobiliary Endoscopy and Endosonography Division</named-content>
<named-content content-type="organisation-division">Pancreas Translational and Clinical Research Center</named-content>
<institution>IRCCS San Raffaele Scientific Institute</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="deo270024-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Vita&#x02010;Salute San Raffaele University</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="deo270024-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>University of Turin</institution>
<city>Turin</city>
<country country="IT">Italy</country>
</aff><aff id="deo270024-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>University Hospitals Gasthuisberg</institution>
<institution>University of Leuven</institution>
<city>Leuven</city>
<country country="BE">Belgium</country>
</aff><aff id="deo270024-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Imelda General Hospital</institution>
<city>Bonheiden</city>
<country country="BE">Belgium</country>
</aff><aff id="deo270024-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<named-content content-type="organisation-division">Amsterdam UMC</named-content>
<institution>University of Amsterdam</institution>
<institution>Amsterdam Gastroenterology Endocrinology &#x00026; Metabolism</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="deo270024-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Pancreatic Surgery Unit</named-content>
<institution>Pancreas Translational and Clinical Research Center</institution>
<institution>IRCCS San Raffaele Scientific Institute</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="deo270024-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Medical Oncology Department</named-content>
<institution>Pancreas Translational and Clinical Research Center</institution>
<institution>IRCCS San Raffaele Scientific Institute</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="deo270024-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Hepatobiliary Surgery Unit</named-content>
<institution>IRCCS San Raffaele Scientific Institute</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Giuseppe Vanella, PancreatoBiliary Endoscopy &#x00026; Endosonography Division, Pancreas Translational &#x00026; Clinical Research Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, 20132, Italy.<break/> Email: <email>vanella.giuseppe@hsr.it</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="72">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70024</elocation-id><history>
<date date-type="rev-recd"><day>15</day><month>9</month><year>2024</year></date>
<date date-type="received"><day>25</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>18</day><month>9</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70024.pdf"/><abstract><title>Abstract</title><sec id="deo270024-sec-0010"><title>Objectives</title><p>Malignant double obstruction, defined as the simultaneous presence of biliary and gastric outlet obstruction, represents a challenging clinical scenario. Previous retrospective experiences have demonstrated shorter dysfunction&#x02010;free survival (DyFS) of endoscopic ultrasound&#x02010;guided choledochoduodenostomy (EUS&#x02010;CDS) versus EUS&#x02010;hepaticogastrostomy (EUS&#x02010;HGS) in this setting, but no prospective evidence is available.</p></sec><sec id="deo270024-sec-0020"><title>Methods</title><p>Twenty consecutive patients with malignant double obstruction, treated with EUS&#x02010;gastroenterostomy (and EUS&#x02010;guided biliary drainage, following a previously failed ERCP, were enrolled in a prospective observational study (ClinicalTrials.gov NCT04813055) comparing EUS&#x02010;CDS versus EUS&#x02010;HGS. Efficacy and safety were evaluated, with Biliary Dysfunctions as the primary outcome and DyFS using Kaplan&#x02010;Meier estimates as a primary measure.</p></sec><sec id="deo270024-sec-0030"><title>Results</title><p>Twenty patients (75% with pancreatic cancer, 50% with metastatic disease) with EUS&#x02010;gastroenterostomy&#x000a0;were included (seven EUS&#x02010;CDS and 13 EUS&#x02010;HGS). No significant difference was detected at baseline. Technical success was 100% in both groups. EUS&#x02010;CDS compared to EUS&#x02010;HGS showed similar clinical success (100% vs. 92.3%, <italic toggle="yes">p</italic> = 0.5), a higher rate of post&#x02010;procedural adverse events (42.9% vs. 7.7%, <italic toggle="yes">p</italic> = 0.067, mostly related to severe/fatal cholangitis in the EUS&#x02010;CDS group) and a higher rate of biliary dysfunctions during follow&#x02010;up (71.4% vs. 16.7%, <italic toggle="yes">p</italic> = 0.002).</p><p>DyFS was significantly shorter in the EUS&#x02010;CDS group (39 [15&#x02013;62] vs. 268 [192&#x02013;344] days, <italic toggle="yes">p</italic> = 0.0023), with a 30&#x02010;days DyFS probability of 57.1% vs. 100% (hazard ratio = 7.8 [1.4&#x02013;44.2]).</p></sec><sec id="deo270024-sec-0040"><title>Conclusions</title><p>In this prospective comparison of patients with malignant double obstruction undergoing EUS&#x02010;gastroenterostomy, treating jaundice with EUS&#x02010;CDS versus EUS&#x02010;HGS resulted in a reduced probability of survival without biliary events and an increased risk of biliary dysfunctions (number needed to harm = 1.8), with detection of severe/fatal cholangitis.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270024-kwd-0001">cholangiopancreatography</kwd><kwd id="deo270024-kwd-0002">cholangitis</kwd><kwd id="deo270024-kwd-0003">endoscopic retrograde</kwd><kwd id="deo270024-kwd-0004">gastric outlet obstruction</kwd><kwd id="deo270024-kwd-0005">jaundice</kwd><kwd id="deo270024-kwd-0006">stent</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="10"/><word-count count="5091"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270024-sec-0050"><title>BACKGROUND</title><p>Jaundice and gastric outlet obstruction (GOO) are frequent manifestations of gastrointestinal malignancies which may negatively impact quality of life and delay oncological treatment. For GOO, growing evidence supports the use of endoscopic ultrasound&#x02010;guided gastroenterostomy (EUS&#x02010;GE) over duodenal self&#x02010;expandable metal stents (dSEMS).<xref rid="deo270024-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270024-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Conversely, there is uncertainty regarding the optimal biliary drainage modality in this scenario, especially when endoscopic retrograde cholangiopancreatography (ERCP) fails. Whereas EUS&#x02010;guided biliary drainage (EUS&#x02010;BD) has proved superior over percutaneous drainage (PTBD),<xref rid="deo270024-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> it is unclear whether EUS&#x02010;guided choledochoduodenostomy (EUS&#x02010;CDS) or EUS&#x02010;guided hepaticogastrostomy (EUS&#x02010;HGS) should be preferred.<xref rid="deo270024-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>The combination of GOO and biliary obstruction (BO), or malignant double obstruction (mDO), represents a challenging clinical scenario since GOO might preclude access to the ampullary region and/or impair EUS&#x02010;BD, which relies on adequate gastroduodenal transit.<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Previous retrospective experiences suggested that EUS&#x02010;HGS results in less and later&#x000a0;biliary dysfunction following either dSEMS<xref rid="deo270024-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> or EUS&#x02010;GE<xref rid="deo270024-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> but no prospective evidence is available. Furthermore, the risk of ascending cholangitis associated with EUS&#x02010;CDS in patients with duodenal obstruction has been reaffirmed by recent evidence from procedures involving lumen&#x02010;apposing metal stents (LAMS).<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>To improve the reliability of these results, this study aimed to prospectively evaluate the long&#x02010;term outcomes of EUS&#x02010;CDS compared to EUS&#x02010;HGS in patients with mDO, where concomitant GOO was treated by EUS&#x02010;GE.</p></sec><sec id="deo270024-sec-0060"><title>METHODS</title><p>All consecutive patients treated for mDO in a single tertiary referral academic institution between July 2021 and October 2023 were enrolled in a Prospective Registry of Therapeutic EUS (PROTECT, ClinicalTrials.gov NCT04813055), with daily follow&#x02010;up during hospitalization and scheduled telephonic follow&#x02010;up every 30 days after discharge. Written informed consent was obtained for the procedures and, specifically, for the registry.</p><p>This prospective study was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice and approved by the Ethics Committee (Id: 178/INT/2020).</p><p>This original cohort does not overlap with any previous publication, including the CABRIOLET retrospective study from the Leuven Amsterdam Milan Study Group.<xref rid="deo270024-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><sec id="deo270024-sec-0070"><title>Inclusion criteria</title><p>Patients were eligible upon receiving EUS&#x02010;GE for GOO and either EUS&#x02010;CDS or EUS&#x02010;HGS for biliary drainage after a failed or impossible ERCP.</p><p>Allocation to one of the two EUS&#x02010;BD modalities was not randomized but based on the performing endoscopist's judgment, taking into consideration the patient's clinical, morphological, and oncological characteristics.</p><p>Inclusion criteria were: (1) age &#x0003e;18 years; (2) ability to provide informed consent; (3) pathologically confirmed malignancy; (4) clinically and morphologically confirmed mDO; (5) having received endoscopic treatment with EUS&#x02010;GE plus either EUS&#x02010;CDS or EUS&#x02010;HGS; and (6) minimum post&#x02010;procedural follow&#x02010;up of 30 days, unless death occurred earlier.</p><p>mDO was defined as the simultaneous presence of malignant BO and GOO.</p><p>BO was defined as a radiologically and endoscopically confirmed biliary stenosis associated with jaundice (bilirubin &#x02265;2 mg/dL).</p><p>GOO was defined as a radiologically and endoscopically confirmed gastroduodenal luminal stenosis associated with a GOO Scoring System (GOOSS<xref rid="deo270024-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>) score &#x0003c;2 (no food intake or ability to tolerate liquids only).</p><p>Exclusion criteria were: (1) benign BO or GOO; and (2) patients receiving biliary treatments other than those under evaluation, including EUS&#x02010;guided antegrade stenting.</p></sec><sec id="deo270024-sec-0080"><title>Procedures</title><p>EUS&#x02010;GE was performed (see Figure&#x000a0;<xref rid="deo270024-fig-0001" ref-type="fig">1a&#x02013;c</xref>) using the Wireless Simplified EUS&#x02010;GE Technique,<xref rid="deo270024-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> involving an oro&#x02010;jejunal tube for jejunal distension and free&#x02010;hand placement of an electrocautery&#x02010;enhanced 20&#x02010;mm LAMS (Hot Axios; Boston Scientific).<xref rid="deo270024-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="deo270024-fig-0001"><label>FIGURE 1</label><caption><p>(a&#x02013;c) Endoscopic ultrasound (EUS)&#x02010;guided gastroenterostomy (EUS&#x02010;GE). (a) Endosonographic appearance of the operative window for EUS&#x02010;GE before lumen&#x02010;apposing metal stents (LAMS) deployment (see the tip of the catheter in the left upper corner). The operative space includes an adequately distended jejunal loop, orientated in the direction of the operative channel of the scope, with the shortest distance possible between the gastric and jejunal lumen; (b) fluoroscopic image showing an oro&#x02010;jejunal tube looped in the first jejunal loop, through which the jejunum is distended (in this case with saline mixed with contrast) and a LAMS released between the stomach and the jejunal loop. (c) Visualization of the jejunal folds through the LAMS after stent release and dilation. (d&#x02013;f) EUS&#x02010;guided choledochoduodenostomy (EUS&#x02010;CDS). (d) Endosonographic appearance of a LAMS placed between the choledochus and the duodenal bulb; (e) endoscopic image of a released proximal flange with bile flowing in the duodenum; (f) fluoroscopic image of a double obstruction managed by EUS&#x02010;GE + EUS&#x02010;CDS (with aerobilia). (g&#x02013;i) EUS&#x02010;guided hepaticogastrostomy. (g) Endosonographic appearance of a 19G needle accessing a branch of a mildly dilated left biliary three through a cushion of hepatic parenchyma; (h) contrast injection confirming the puncture of a branch of the left biliary tree; (i) endoscopic appearance of a gastroenteric LAMS and of a hepatogastric SEMS.</p></caption><graphic xlink:href="DEO2-5-e70024-g001" position="anchor" id="jats-graphic-1"/></fig><p>EUS&#x02010;CDS was performed (see Figure&#x000a0;<xref rid="deo270024-fig-0001" ref-type="fig">1d&#x02013;f</xref>) through the free&#x02010;hand placement of an 8 &#x000d7; 8 or a 6 &#x000d7; 8 mm LAMS (Hot Axios; Boston Scientific) between the common bile duct and the duodenum.<xref rid="deo270024-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>EUS&#x02010;HGS was performed (see Figure&#x000a0;<xref rid="deo270024-fig-0001" ref-type="fig">1g&#x02013;i</xref>) by puncturing a left intrahepatic biliary branch through a 19G needle, followed by contrast injection, 0.035&#x02010;inch guidewire cannulation, tract creation using a 6Fr cystotome (Endoflex, GmbH), and placement of a 10 &#x000d7; 100 or 10 &#x000d7; 80 mm partially covered stent (Giobor; Taewoong).<xref rid="deo270024-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>All procedures were performed by (or under the direct supervision of) two expert endoscopists (Paolo Giorgio Arcidiacono and Giuseppe Vanella) with extensive experience in therapeutic EUS (at least 50 procedures/year) and ERCP (at least 300 procedures/year) at the date of the first included patient.</p></sec><sec id="deo270024-sec-0090"><title>Outcome measures</title><p>The primary outcome of this study was biliary dysfunction, defined as the new onset of biochemical evidence of cholestasis or cholangitis accompanied by biliary dilation following initial clinical success, requiring hospitalization due to an escalation of medical care or biliary reintervention. The primary endpoints for this outcome were the rate (proportion) of biliary dysfunction<xref rid="deo270024-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and dysfunction&#x02010;free survival (DyFS), defined as the time from the procedure to the first occurrence of dysfunction, death, surgical resection, or the last clinical follow&#x02010;up, whichever occurred first. Prospective surveillance began on the day the two procedures (EUS&#x02010;BD plus EUS&#x02010;GE) coexisted, regardless of the order in which they were performed.</p><p>Technical success was defined as the successful completion of the planned procedures.</p><p>Among technically successful procedures, clinical success was defined as achieving a &#x0003e;50% reduction in bilirubin levels within 14 days after stent placement for BO,<xref rid="deo270024-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and a postprocedural GOOSS &#x02265;2 (ability to eat at least soft solids) within 14 days after stent placement for GOO.<xref rid="deo270024-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Adverse events (AEs) were scored through the ASGE lexicon.<xref rid="deo270024-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Dysfunctions and reinterventions of EUS&#x02010;CDS were classified according to the Leuven Amsterdam Milan Study (L.A.M.S.) Classification.<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Procedural time (minutes) was limited to the interventional EUS&#x02010;BD fraction, ranging from the diagnostic EUS scan evaluating the target biliary structure to the completion of stent release.</p></sec><sec id="deo270024-sec-0100"><title>Statistics</title><p>Descriptive statistics are reported as frequencies (proportions) and medians (interquartile range) after the exclusion of normality. Comparisons between groups were performed by the Chi&#x02010;square or Fisher exact test for qualitative data and the Mann&#x02010;Whitney test for quantitative data, as appropriate.</p><p>Biliary dysfunction and DyFS were calculated using Kaplan&#x02010;Meier estimates, with censoring at the date of the last clinical follow&#x02010;up, death, or surgical resection (removing the biliary drainage), whichever came first. Log&#x02010;rank test was used to compare EUS&#x02010;CDS and EUS&#x02010;HGS. Due to the exploratory nature of this study, a formal sample size estimation was not conducted. A <italic toggle="yes">p</italic>&#x02010;value &#x0003c;0.05 was considered significant. All analyses were performed using Medcalc.</p></sec></sec><sec id="deo270024-sec-0110"><title>RESULTS</title><p>During the study interval, 325 patients were included in the PROTECT Registry (see <bold>METHODS</bold>). Of these, 115 patients received EUS&#x02010;GE for GOO, 59 received EUS&#x02010;CDS, and 37 received EUS&#x02010;HGS.</p><p>For the scope of this study, 20 patients fulfilled the inclusion criteria, as they experienced mDO and underwent both EUS&#x02010;GE for GOO and EUS&#x02010;BD after failed/impossible ERCP: seven patients received EUS&#x02010;CDS and 13 EUS&#x02010;HGS.</p><sec id="deo270024-sec-0120"><title>Baseline characteristics</title><p>Most patients (75%) had pancreatic cancer, and 50% had metastatic disease (see Table&#x000a0;<xref rid="deo270024-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="deo270024-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient's characteristics of patients in the endoscopic ultrasound&#x02010;guided choledochoduodenostomy (EUS&#x02010;CDS) and hepaticogastrostomy (EUS&#x02010;HGS) groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">EUS&#x02010;CDS, <italic toggle="yes">n</italic> = 7</th><th align="left" rowspan="1" colspan="1">EUS&#x02010;HGS, <italic toggle="yes">n</italic> = 13</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years, median [IQR]</td><td align="left" rowspan="1" colspan="1">63 [61&#x02013;76]</td><td align="left" rowspan="1" colspan="1">67 [60&#x02013;74]</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">2 (28.6%)</td><td align="left" rowspan="1" colspan="1">9 (69.2%)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA score</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">5 (71.4%)</td><td align="left" rowspan="1" colspan="1">8 (61.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2 (28.6%)</td><td align="left" rowspan="1" colspan="1">5 (38.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Charlson Comorbidity Index, median [IQR]</td><td align="left" rowspan="1" colspan="1">4 [4&#x02013;8]</td><td align="left" rowspan="1" colspan="1">8 [6&#x02013;9]</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>, median [IQR]</td><td align="left" rowspan="1" colspan="1">21.5 [18.4&#x02013;24.4]</td><td align="left" rowspan="1" colspan="1">19.5 [18.6&#x02013;23.4]</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreatic cancer</td><td align="left" rowspan="1" colspan="1">6 (85.7%)</td><td align="left" rowspan="1" colspan="1">9 (69.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Duodenal/ampullary cancer</td><td align="left" rowspan="1" colspan="1">1 (14.3%)</td><td align="left" rowspan="1" colspan="1">2 (15.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Others (gastric cancer/gallbladder cancer)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (15.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Oncological staging</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Metastatic</td><td align="left" rowspan="1" colspan="1">3 (42.9%)</td><td align="left" rowspan="1" colspan="1">8 (61.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Localized</td><td align="left" rowspan="1" colspan="1">4 (57.1%)</td><td align="left" rowspan="1" colspan="1">5 (38.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Level of GI stenosis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gastroenterostomy in post&#x02010;surgical anatomy</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">
<p>3 (23.1%)</p>
<p>
<italic toggle="yes">N</italic> = 1 Roux&#x02010;en&#x02010;Y gastrectomy</p>
<p>
<italic toggle="yes">N</italic> = 2 Pancreatic surgeries</p>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type 1 (above the ampulla)</td><td align="left" rowspan="1" colspan="1">3 (42.9%)</td><td align="left" rowspan="1" colspan="1">4 (30.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type 2 (at the ampulla)</td><td align="left" rowspan="1" colspan="1">4 (57.1%)</td><td align="left" rowspan="1" colspan="1">6 (46.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Reason for EUS&#x02010;BD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;surgical anatomy</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">3 (23.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Papillary infiltration</td><td align="left" rowspan="1" colspan="1">5 (71.4%)</td><td align="left" rowspan="1" colspan="1">8 (61.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Failed ERCP</td><td align="left" rowspan="1" colspan="1">2 (28.6%)</td><td align="left" rowspan="1" colspan="1">2 (15.4%)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo270024-tbl1-note-0001"><p>Abbreviations: ASA, American Anesthesiological Association; ERCP, endoscopic retrograde cholangiopancreatography; EUS&#x02010;BD, EUS&#x02010;guided biliary drainage; GI, gastrointestinal; IQR, interquartile range.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>No statistically significant difference between groups was detected at baseline. A non&#x02010;significant higher prevalence of post&#x02010;surgical anatomy was present in the EUS&#x02010;HGS group, together with a trend toward more advanced oncological staging (see Table&#x000a0;<xref rid="deo270024-tbl-0001" ref-type="table">1</xref>).</p><p>EUS&#x02010;GE and EUS&#x02010;BD combinations were created with a median interval of 8 [0&#x02013;38] days. Nine patients underwent same&#x02010;session double drainage (five EUS&#x02010;HGS; four EUS&#x02010;CDS). Six patients first received EUS&#x02010;GE, while five patients first received EUS&#x02010;BD, with a median latency of 36 [9&#x02013;47] days. Of note, amongst patients with known GOO, the endoscopist tended to favor EUS&#x02010;HGS (83%), compared to the more balanced adoption of the two EUS&#x02010;BD modalities when BO was treated first (three EUS&#x02010;HGS in post&#x02010;surgical anatomy and two EUS&#x02010;CDS in normal anatomy).</p></sec><sec id="deo270024-sec-0130"><title>Outcomes</title><p>No patient was lost to follow&#x02010;up or had missing data for the outcomes of interest.</p><p>Technical and clinical success for EUS&#x02010;GE were 100% and 95% respectively, with a median pre&#x02010; and post&#x02010;procedural GOOSS score of 0 [0&#x02013;0] versus 2 [2&#x02013;3], respectively.</p><p>Regarding EUS&#x02010;BD, technical success was 100% for both groups, with a significantly shorter procedural time for EUS&#x02010;CDS compared to EUS&#x02010;HGS (12.5 [4&#x02013;15] min vs. 50 [34.5&#x02013;58.5] min, respectively; see Table&#x000a0;<xref rid="deo270024-tbl-0002" ref-type="table">2</xref>). The procedures showed similar clinical success (100% vs. 92.3%, <italic toggle="yes">p</italic> = 0.5).</p><table-wrap position="float" id="deo270024-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Outcomes of endoscopic ultrasound&#x02010;guided choledochoduodenostomy versus hepaticogastrostomy combined with endoscopic ultrasound&#x02010;guided gastroenterostomy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">EUS&#x02010;CDS, <italic toggle="yes">n</italic> = 7</th><th align="left" rowspan="1" colspan="1">EUS&#x02010;HGS, <italic toggle="yes">n</italic> = 13</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Technical success, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">7 (100%)</td><td align="left" rowspan="1" colspan="1">13 (100%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median procedure time, minutes [IQR]</td><td align="left" rowspan="1" colspan="1">12.5 [4&#x02013;15]</td><td align="left" rowspan="1" colspan="1">50 [34.5&#x02013;58.5]</td><td align="left" rowspan="1" colspan="1">
<bold>0.0006</bold>*</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical success, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">7 (100%)</td><td align="left" rowspan="1" colspan="1">12 (92.3%)</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">3 (42.9%)</td><td align="left" rowspan="1" colspan="1">1 (7.7%)</td><td align="left" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" rowspan="1" colspan="1">ASGE lexicon</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">1 (14.3%)
<list list-type="simple" id="deo270024-list-0001"><list-item><p>Cholangitis requiring reintervention</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">1 (14.3%)
<list list-type="simple" id="deo270024-list-0002"><list-item><p>Cholangitis requiring reintervention</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">1 (7.7%)
<list list-type="simple" id="deo270024-list-0003"><list-item><p>Post&#x02010;ERCP pancreatitis (placement of retrograde SEMS in the right liver lobe)</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatal</td><td align="left" rowspan="1" colspan="1">1 (14.3%)
<list list-type="simple" id="deo270024-list-0004"><list-item><p>Cholangitis complicated by septic shock and DIC</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Biliary dysfunctions<xref rid="deo270024-tbl2-note-0003" ref-type="table-fn">
<sup>&#x00026;</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">5 (71.4%)</td><td align="left" rowspan="1" colspan="1">2 (16.7%)</td><td align="left" rowspan="1" colspan="1">
<p>
<bold>0.02</bold>*</p>
<p>RR = 4.3 [1.1&#x02013;16.5]</p>
<p>NNH = 1.8</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Median hospital stay, days [IQR]</td><td align="left" rowspan="1" colspan="1">5.5 [5&#x02013;19]</td><td align="left" rowspan="1" colspan="1">7 [5&#x02013;11.8]</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Median FU, days [IQR]</td><td align="left" rowspan="1" colspan="1">64 [27&#x02013;102]</td><td align="left" rowspan="1" colspan="1">82 [22&#x02013;217]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Dysfunction&#x02010;free survival<xref rid="deo270024-tbl2-note-0004" ref-type="table-fn">
<sup>$</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>
<bold>0.0023</bold>*</p>
<p>HR = 7.8 [1.4&#x02013;44.2]</p>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean estimated DyFS, days (95% CI)</td><td align="left" rowspan="1" colspan="1">39 (15&#x02013;62)</td><td align="left" rowspan="1" colspan="1">268 (192&#x02013;344)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">DyFS probability</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">30 days</td><td align="left" rowspan="1" colspan="1">57.1%</td><td align="left" rowspan="1" colspan="1">100%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">3 months</td><td align="left" rowspan="1" colspan="1">0%</td><td align="left" rowspan="1" colspan="1">87.5%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean estimated OS<xref rid="deo270024-tbl2-note-0004" ref-type="table-fn">
<sup>$</sup>
</xref>, days (95% CI)</td><td align="left" rowspan="1" colspan="1">105 (38&#x02013;171)</td><td align="left" rowspan="1" colspan="1">133 (67&#x02013;198)</td><td align="left" rowspan="1" colspan="1">0.9</td></tr></tbody></table><table-wrap-foot><fn id="deo270024-tbl2-note-0001"><p>Abbreviations: ASGE, American Society for Gastrointestinal Endoscopy; CI, confidence interval; DIC, disseminated intravascular coagulation; DyFS, dysfunction&#x02010;free survival; EUS&#x02010;CDS, endoscopic ultrasound&#x02010;guided choledochoduodenostomy; EUS&#x02010;HGS, endoscopic ultrasound&#x02010;guided hepaticogastrostomy; FU, follow&#x02010;up; NNH, number needed to harm; OS, overall survival; RR, relative risk; SEMS, self&#x02010;expandable metal stents</p></fn><fn id="deo270024-tbl2-note-0002"><label>*</label><p>Statistically significant.</p></fn><fn id="deo270024-tbl2-note-0003"><label>
<sup>&#x00026;</sup>
</label><p>Among patients with clinical success and &#x02265;30 days of FU.</p></fn><fn id="deo270024-tbl2-note-0004"><label>
<sup>$</sup>
</label><p>At Kaplan Meier estimator, with a log&#x02010;rank test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>However, a higher rate of post&#x02010;procedural AEs was noticed in the EUS&#x02010;CDS group (42.9% vs. 7.7%, p = 0.067). The three AEs in the EUS&#x02010;CDS group presented with septic shock due to cholangitis, occurring a median of 4 [2&#x02013;7] days post&#x02010;procedure. One event was fatal, another required endoscopic reintervention with through&#x02010;the&#x02010;LAMS anterograde stenting due to stent obstruction, and the third was managed with antibiotic therapy. The only observed AE in the EUS&#x02010;HGS group was a moderate post&#x02010;ERCP pancreatitis in a patient receiving same&#x02010;session retrograde metal stenting of the right liver lobe, EUS&#x02010;HGS for the left liver lobe and EUS&#x02010;GE for duodenal invasion.</p></sec><sec id="deo270024-sec-0140"><title>Biliary dysfunctions</title><p>During follow&#x02010;up, the EUS&#x02010;CDS group experienced a significantly higher rate of biliary dysfunctions (71.4% vs. 16.7%, <italic toggle="yes">p</italic> = 0.02, relative risk = 4.3 [1.1&#x02013;16.5]), resulting in a Number Needed to Harm of 1.8.</p><p>All dysfunctions in the EUS&#x02010;CDS group (<italic toggle="yes">n</italic> = 5) were related to ascending cholangitis from food impaction (type 5 according to the L.A.M.S. Classification,<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> see Figure&#x000a0;<xref rid="deo270024-fig-0002" ref-type="fig">2a&#x02013;c</xref>). These were managed in one case conservatively with antibiotic therapy, in two cases with antegrade stenting through&#x02010;the&#x02010;LAMS (type D3 reintervention),<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270024-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> in one case with coaxial double&#x02010;pigtail stenting (type A reintervention),<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270024-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and in another case with balloon swipes (type B reintervention).<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270024-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="deo270024-fig-0002"><label>FIGURE 2</label><caption><p>(a&#x02013;c) Endoscopic ultrasound&#x02010;choledochoduodenostomy (EUS&#x02010;CDS) dysfunction. (a) During the follow&#x02010;up of a combination of EUS&#x02010;gastroenterostomy (EUS&#x02010;GE) + EUS&#x02010;CDS, the patient experienced cholangitis, and a gastrointestinal contrast series showed reflux of contrast medium inside the biliary tree through the lumen&#x02010;apposing metal stents (LAMS). (b) At endoscopic reintervention, food impaction was visible inside the choledocho&#x02010;bulbar LAMS; (c) balloon swipes were performed to extract food debris and sludge from the biliary duct. (d&#x02013;f) EUS&#x02010;hepaticogastrostomy (EUS&#x02010;HGS) dysfunction. (d) During follow&#x02010;up of a combination of EUS&#x02010;GE + EUS&#x02010;HGS, the patient experienced recurrent jaundice and cholangitis. At endoscopic revision, the hepatogastric SEMS was visibly obstructed and showed an outflow of pus. (e) The SEMS was cannulated with a Fogarty balloon over the wire and balloon swipes were performed to clear accumulated debris; (f) at subsequent cholangiography, the end of the hepatogastric SEMS was angulated with respect to the direction of the left hepatic duct, and therefore biliary drainage was facilitated by anterograde placement of a transpapillary SEMS.</p></caption><graphic xlink:href="DEO2-5-e70024-g003" position="anchor" id="jats-graphic-3"/></fig><p>The two dysfunctions in the EUS&#x02010;HGS group were managed in one case with balloon swipes and anterograde transpapillary stenting (see Figure&#x000a0;<xref rid="deo270024-fig-0002" ref-type="fig">2d&#x02013;f</xref>), while the other was managed conservatively with antibiotic therapy due to the patient's advanced stage of disease.</p><p>At Kaplan&#x02010;Meier estimator (Figure&#x000a0;<xref rid="deo270024-fig-0003" ref-type="fig">3b</xref>), EUS&#x02010;CDS in this setting showed a significantly shorter DyFS (39 [15&#x02013;62] vs. 268 [192&#x02013;344] days, log&#x02010;rank <italic toggle="yes">p</italic> = 0.0023, Hazard Ratio = 7.8 [1.4&#x02013;44.2]), with a 30&#x02010;days DyFS probability of 53.6% vs. 100%. No major differences in median Overall Survival were detected (EUS&#x02010;CDS: 105 [38&#x02013;171] days; EUS&#x02010;HGS: 133 [67&#x02013;198] days, <italic toggle="yes">p</italic> = 0.9; Figure&#x000a0;<xref rid="deo270024-fig-0003" ref-type="fig">3a</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270024-fig-0003"><label>FIGURE 3</label><caption><p>Kaplan&#x02010;Meier analysis of overall (a) and dysfunction&#x02010;free survival (b). (a) No difference in overall survival was noticed between the EUS&#x02010;choledochoduodenostomy (EUS&#x02010;CDS) and the EUS&#x02010;hepaticogastrostomy (EUS&#x02010;HGS) groups. (b) In the setting of combined biliary and alimentary obstruction, the latter treated by EUS&#x02010;gastroenterostomy, the EUS&#x02010;CDS group showed a significantly shorter survival without biliary events compared to the EUS&#x02010;HGS group (log&#x02010;rank test <italic toggle="yes">p</italic> = 0.0023).</p></caption><graphic xlink:href="DEO2-5-e70024-g002" position="anchor" id="jats-graphic-5"/></fig></sec></sec><sec id="deo270024-sec-0150"><title>DISCUSSION</title><p>In this first prospective comparative study, EUS&#x02010;CDS exhibited a higher incidence of early cholangitis and a significantly shorter DyFS compared to EUS&#x02010;HGS, despite similar technical and clinical success rates. These data raise significant concerns about performing EUS&#x02010;CDS in case of double obstruction.</p><p>Managing mDO is complex. Duodenal obstruction can hinder ERCP or reduce the effectiveness of technically successful biliary drainage. To treat GOO, dSEMS have proved less effective, both in the short and long term, when compared to newer solutions such as EUS&#x02010;GE. In a recent meta&#x02010;analysis,<xref rid="deo270024-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> EUS&#x02010;GE versus dSEMS demonstrated higher clinical success (94% versus 86%, pooled odds ratio (OR) = 2.72 [1.86&#x02013;3.97,&#x000a0;<italic toggle="yes">I</italic>
<sup>2</sup> = 0]) and significantly lower need for reinterventions (4% versus 25%, OR = 0.13 [0.07&#x02013;0.28],&#x000a0;<italic toggle="yes">I</italic>
<sup>2</sup> = 13]). These results are consistent even in prospective<xref rid="deo270024-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> and randomized studies<xref rid="deo270024-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> on this comparison. Notably, dSEMS had a higher AEs rate than EUS&#x02010;GE (20% versus 9%),<xref rid="deo270024-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> despite EUS&#x02010;GE being perceived as a significantly more challenging procedure with a higher risk of misdeployment and perforation and a steeper learning curve.<xref rid="deo270024-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> This might depend on the higher risk of bleeding of metal stents crossing a neoplastic infiltration, as well as on the increased risk of pancreatitis and cholangitis resulting when dSEMS are placed across the papilla,<xref rid="deo270024-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo270024-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> either due to direct interference with biliary stents or increased duodenobiliary reflux. Finally, achieving biliary drainage through a dSEMS makes it more difficult to locate or access the papilla, or to place a biliary stent through the meshes; success rates for biliary drainage in retrospective studies vary between 34% and 93%, reflecting selection biases inherent in retrospective evaluations.<xref rid="deo270024-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270024-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270024-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270024-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>EUS&#x02010;BD is increasingly used in mDO. A recent study including 39 patients showed that EUS&#x02010;BD had higher technical (95% versus 56%; <italic toggle="yes">p</italic> &#x0003c; 0.01) and clinical success rates (91% versus 52%; <italic toggle="yes">p</italic> = 0.01) compared to ERCP, with similar invasiveness and long&#x02010;term patency.<xref rid="deo270024-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Additionally, comparing EUS&#x02010;HGS with ERCP or PTBD in the setting of indwelling DS, a trend towards lower complication rates and fewer reinterventions was observed for EUS&#x02010;HGS.<xref rid="deo270024-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Despite recent literature on mDO mostly focusing on patients already treated with DS, there is growing interest in procedural combinations involving EUS&#x02010;GE, due to the aforementioned advantages. The first study exploring this setting was an uncontrolled retrospective series (<italic toggle="yes">n</italic> = 23) describing same&#x02010;session EUS&#x02010;GE and EUS&#x02010;HGS, which showed high clinical success rates and a relatively low AEs rate.<xref rid="deo270024-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>The L.A.M.S. Group published a multicenter retrospective study comparing different endoscopic combinations for treating mDO which suggested that combinations involving EUS&#x02010;GE achieve better long&#x02010;term outcomes compared to dSEMS and that either transpapillary stenting (via ERCP or antegrade stenting) or EUS&#x02010;HGS is associated with fewer symptom recurrences. Conversely, EUS&#x02010;CDS in this scenario showed lower primary success rates and frequent dysfunctions, regardless of whether GOO was managed by dSEMS or EUS&#x02010;GE.<xref rid="deo270024-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> These data align with recent reports highlighting an increased risk of EUS&#x02010;CDS dysfunction in case of duodenal invasion or the presence of dSEMS.<xref rid="deo270024-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270024-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Although EUS&#x02010;CDS might generally be preferred over EUS&#x02010;HGS for its simplicity and wider availability,<xref rid="deo270024-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> our small prospective study confirms that EUS&#x02010;HGS significantly reduces the risk of short&#x02010; and long&#x02010;term AEs in the setting of mDO, as it nullifies the risk of ascending cholangitis. All procedures were performed by endoscopists experienced in therapeutic EUS, and most AEs did not occur during the procedure but developed after a time interval, thus suggesting that they stem from EUS&#x02010;CDS's intrinsic limitations in this context rather than from operator inexperience or procedural errors.</p><p>Indeed, even after resolving GOO with EUS&#x02010;GE, the risk of food particles accumulating in the bulb where EUS&#x02010;CDS is positioned increases the likelihood of ascending cholangitis. This problem is potentially mitigated with EUS&#x02010;HGS, as the tubular stent design with long intragastric protrusion counteracts food influx; unlike the LAMS used in EUS&#x02010;CDS which reduces the interluminal distance between the duodenum and biliary tree.</p><p>This study has several limitations. First, despite the prospective inclusion, the allocation to EUS&#x02010;CDS versus EUS&#x02010;HGS was not randomized, and several factors might have influenced the endoscopist's decision. In some cases, EUS&#x02010;HGS was the only option in patients where the duodenum was not reachable (<italic toggle="yes">n</italic> = 4 non&#x02010;viable pyloric/bulbar stenosis; <italic toggle="yes">n</italic> = 3 post&#x02010;surgical anatomies); conversely EUS&#x02010;CDS might have been preferred in patients with more distal duodenal stenosis and viable duodenal bulb (<italic toggle="yes">n</italic> = 4) or in those where GOO was not yet clinically evident at the time of EUS&#x02010;BD (<italic toggle="yes">n</italic> = 3). Yet, there was a quota of patients in which the two procedures were both technically feasible, and one was chosen over the other, due to factors other than the anatomy, for example, potential future surgical candidacy, referring physician's preference, or simply lack of high&#x02010;quality evidence on the best EUS&#x02010;BD modality in this scenario. Moreover, there was a non&#x02010;significant temporal trend towards preferring EUS&#x02010;HGS in the latter part of the study period, due to accumulating evidence supporting this approach in the setting of concomitant GOO. Although all these factors might introduce a selection bias, baseline differences between the two groups, including the level of stenosis, were not statistically significant (see Table&#x000a0;<xref rid="deo270024-tbl-0001" ref-type="table">1</xref>), but might become evident in a larger sample size. Nevertheless, regardless of the reasons that led to the preference for one technique over the other, we genuinely believe that this prospective series remains a unique opportunity to compare the patency of the two EUS&#x02010;BD modalities in this specific setting of double obstruction, where GOO was treated with EUS&#x02010;GE.</p><p>Secondly, in this series there was no routine adoption of prophylactic coaxial double&#x02010;pigtail plastic stents during EUS&#x02010;CDS: the impact of this maneuver on the risk of ascending cholangitis remains to be proven, and the results of a randomized controlled trial are eagerly awaited.<xref rid="deo270024-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Thirdly, these results were obtained from a tertiary referral center with significant expertise in both extrahepatic (EUS&#x02010;CDS) and intrahepatic (EUS&#x02010;HGS) biliary access, which may limit the generalizability of the findings. This last point prompts two distinct considerations. The first is that mDO represents a complex situation that might be better managed in tertiary referral centers, as standardized for complex surgery.<xref rid="deo270024-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> The second is that whenever a center opts for EUS&#x02010;CDS and the problem of ascending cholangitis emerges, the choledochoduodenal LAMS can be exploited to perform rescue maneuvers, such as placement of coaxial double&#x02010;pigtail plastic stents&#x000a0;or conversion to transpapillary stenting.<xref rid="deo270024-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>Despite these limitations, this is the first prospective study comparing EUS&#x02010;HGS with EUS&#x02010;CDS in the setting of mDO treated exclusively by EUS&#x02010;GE. The prospective nature of post&#x02010;procedural follow&#x02010;up reduces the risk of underdetection of clinical events, even when managed in peripheral centers. In addition, no patient was lost to follow&#x02010;up, while the short follow&#x02010;up of this cohort simply reflects the reduced overall survival of patients with this condition, further highlighting the prognostic value of mDO.</p><p>To conclude, within the context of mDO, even when GOO is treated by EUS&#x02010;GE, EUS&#x02010;CDS reveals an unacceptably high risk of early and severe reflux cholangitis, a phenomenon seemingly less common with EUS&#x02010;HGS. To substantiate this proof&#x02010;of&#x02010;concept evidence, randomized controlled trials&#x000a0;would be essential, though ethical considerations arise regarding the acceptability of exposing patients in the EUS&#x02010;CDS arm to such a heightened risk of biliary events. It remains to be seen whether universal prophylactic coaxial double&#x02010;pigtail plastic stents placement and further development of LAMS design will overcome the risk difference with EUS&#x02010;HGS, considering the easier execution and widespread availability of EUS&#x02010;CDS.</p></sec><sec sec-type="COI-statement" id="deo270024-sec-0160"><title>CONFLICT OF INTEREST STATEMENT</title><p>Giuseppe Vanella reports lecture fees from Boston Scientific and travel grants from Euromedical. Michiel Bronswijk received grant support from Boston Scientific. Roy LJ van Wanrooij holds a consultancy agreement with Boston Scientific. Schalk van der Merwe has consultancy agreements with Cook Medical, Pentax, and Olympus and chairs the Boston Scientific board in Therapeutic Biliopancreatic Endoscopy and the Cook Medical board in Interventional endoscopy. All other authors declare no conflict of interest.</p></sec><sec id="deo270024-sec-0170"><title>ETHICS STATEMENT</title><p>Approval of the research protocol by an Institutional Reviewer Board: ID: <bold>178/INT/2020</bold>
</p><p>Informed Consent: <bold>Yes,</bold> for the procedures, and for the observational prospective registry.</p><p>Registry and the registration no. of the study/trial: <bold>ClinicalTrials.gov NCT04813055</bold>
</p><p>Animal Studies: <bold>N/A</bold>.</p></sec></body><back><ref-list id="deo270024-bibl-0001"><title>REFERENCES</title><ref id="deo270024-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270024-cit-0001">
<string-name>
<surname>Vanella</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dell'Anna</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Capurso</surname>
<given-names>G</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;guided gastroenterostomy for management of malignant gastric outlet obstruction: A prospective cohort study with matched comparison with enteral stenting</article-title>. <source>Gastrointest Endosc</source>
<year>2023</year>; <volume>98</volume>: <fpage>337</fpage>&#x02013;<lpage>347</lpage>.<pub-id pub-id-type="pmid">37094692</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270024-cit-0002">
<string-name>
<surname>Teoh</surname>
<given-names>AYB</given-names>
</string-name>, <string-name>
<surname>Lakhtakia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tarantino</surname>
<given-names>I</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic ultrasonography&#x02010;guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA&#x02010;GOO): A multicentre randomised controlled trial</article-title>. <source>Lancet Gastroenterol Hepatol</source>
<year>2024</year>; <volume>9</volume>: <fpage>124</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">38061378</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270024-cit-0003">
<string-name>
<surname>Sharaiha</surname>
<given-names>RZ</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kamal</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Efficacy and safety of EUS&#x02010;guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: A systematic review and meta&#x02010;analysis</article-title>. <source>Gastrointest Endosc</source>
<year>2017</year>; <volume>85</volume>: <fpage>904</fpage>&#x02013;<lpage>914</lpage>.<pub-id pub-id-type="pmid">28063840</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270024-cit-0004">
<string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fang</surname>
<given-names>J</given-names>
</string-name>. <article-title>Comparison of choledochoduodenostomy and hepaticogastrostomy for EUS&#x02010;guided biliary drainage: A meta&#x02010;analysis</article-title>. <source>Front Surg</source>
<year>2022</year>; <volume>9</volume>: <elocation-id>811005</elocation-id>.<pub-id pub-id-type="pmid">35356500</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270024-cit-0005">
<string-name>
<surname>Vanella</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bronswijk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dell'Anna</surname>
<given-names>G</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Classification, risk factors, and management of lumen apposing metal stent dysfunction during follow&#x02010;up of endoscopic ultrasound&#x02010;guided choledochoduodenostomy: Multicenter evaluation from the Leuven&#x02010;Amsterdam&#x02010;Milan Study Group</article-title>. <source>Dig Endosc</source>
<year>2023</year>; <volume>35</volume>: <fpage>377</fpage>&#x02013;<lpage>388</lpage>.<pub-id pub-id-type="pmid">36177532</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270024-cit-0006">
<string-name>
<surname>Ogura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chiba</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Masuda</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Comparison of the clinical impact of endoscopic ultrasound&#x02010;guided choledochoduodenostomy and hepaticogastrostomy for bile duct obstruction with duodenal obstruction</article-title>. <source>Endoscopy</source>
<year>2016</year>; <volume>48</volume>: <fpage>156</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">26382307</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270024-cit-0007">
<string-name>
<surname>Vanella</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bronswijk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van Wanrooij</surname>
<given-names>RL</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Combined endoscopic mAnagement of BiliaRy and gastrIc OutLET obstruction (CABRIOLET Study): A multicenter retrospective analysis</article-title>. <source>DEN Open</source>
<year>2022</year>; <volume>3</volume>: <elocation-id>e132</elocation-id>.<pub-id pub-id-type="pmid">35898844</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270024-cit-0008">
<string-name>
<surname>Adler</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Baron</surname>
<given-names>TH</given-names>
</string-name>. <article-title>Endoscopic palliation of malignant gastric outlet obstruction using self&#x02010;expanding metal stents: Experience in 36 patients</article-title>. <source>Am J Gastroenterol</source>
<year>2002</year>; <volume>97</volume>: <fpage>72</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">11808972</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270024-cit-0009">
<string-name>
<surname>Bronswijk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vanella</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Petrone</surname>
<given-names>MC</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;guided gastroenterostomy: Less is more! The wireless EUS&#x02010;guided gastroenterostomy simplified technique</article-title>. <source>VideoGIE</source>
<year>2020</year>; <volume>5</volume>: <fpage>442</fpage>.</mixed-citation></ref><ref id="deo270024-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270024-cit-0010">
<string-name>
<surname>Vanella</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bronswijk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maleux</surname>
<given-names>G</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;guided intrahepatic biliary drainage: A large retrospective series and subgroup comparison between percutaneous drainage in hilar stenoses or postsurgical anatomy</article-title>. <source>Endosc Int Open</source>
<year>2020</year>; <volume>8</volume>: <fpage>e1782</fpage>&#x02013;<lpage>1794</lpage>.<pub-id pub-id-type="pmid">33269311</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270024-cit-0011">
<string-name>
<surname>Isayama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yasuda</surname>
<given-names>I</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>TOKYO criteria 2014 for transpapillary biliary stenting</article-title>. <source>Dig Endosc</source>
<year>2015</year>; <volume>27</volume>: <fpage>259</fpage>&#x02013;<lpage>264</lpage>.<pub-id pub-id-type="pmid">25209944</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270024-cit-0012">
<string-name>
<surname>Cotton</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Eisen</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Aabakken</surname>
<given-names>L</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>A lexicon for endoscopic adverse events: Report of an ASGE workshop</article-title>. <source>Gastrointest Endosc</source>
<year>2010</year>; <volume>71</volume>: <fpage>446</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">20189503</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270024-cit-0013">
<string-name>
<surname>Vanella</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dell'Anna</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>van Wanrooij</surname>
<given-names>RL</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Managing dysfunctions and reinterventions in endoscopic ultrasound&#x02010;guided choledochoduodenostomy with lumen apposing metal stents: An illustrated technical review (with videos)</article-title>. <source>Dig Endosc</source>
<year>2024</year>; <volume>36</volume>: <fpage>481</fpage>&#x02013;<lpage>491</lpage>.<pub-id pub-id-type="pmid">37852797</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270024-cit-0014">
<string-name>
<surname>Asghar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forcione</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Puli</surname>
<given-names>SR</given-names>
</string-name>. <article-title>Endoscopic ultrasound&#x02010;guided gastroenterostomy versus enteral stenting for gastric outlet obstruction: A systematic review and meta&#x02010;analysis</article-title>. <source>Ther Adv Gastroenterol</source>
<year>2024</year>; <volume>17</volume>: <elocation-id>17562848241248219</elocation-id>.</mixed-citation></ref><ref id="deo270024-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270024-cit-0015">
<string-name>
<surname>De Ponthaud</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bozkirli</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>
<given-names>GEM</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Management of malignant gastric outlet obstruction (mGOO) due to pancreatic cancer in the era of EUS&#x02010;Gastrojejunostomy: An international practice survey and case vignette study by Pancreas 2000 from the European Pancreatic Club</article-title>. <source>Surg Endosc</source>
<year>2024</year>; <volume>38</volume>: <fpage>3231</fpage>&#x02013;<lpage>3240</lpage>.<pub-id pub-id-type="pmid">38649494</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270024-cit-0016">
<string-name>
<surname>Kaneko</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ishiwatari</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Asakura</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Biliary obstruction and pancreatitis after duodenal stent placement in the descending duodenum: A retrospective study</article-title>. <source>BMC Gastroenterol</source>
<year>2022</year>; <volume>22</volume>: <fpage>257</fpage>.<pub-id pub-id-type="pmid">35597896</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270024-cit-0017">
<string-name>
<surname>Hamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Isayama</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: An analysis using a time&#x02010;dependent covariate</article-title>. <source>Surg Endosc</source>
<year>2013</year>; <volume>27</volume>: <fpage>1243</fpage>&#x02013;<lpage>1248</lpage>.<pub-id pub-id-type="pmid">23073685</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270024-cit-0018">
<string-name>
<surname>Mutignani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tringali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>SG</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Combined endoscopic stent insertion in malignant biliary and duodenal obstruction</article-title>. <source>Endoscopy</source>
<year>2007</year>; <volume>39</volume>: <fpage>440</fpage>&#x02013;<lpage>447</lpage>.<pub-id pub-id-type="pmid">17516351</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270024-cit-0019">
<string-name>
<surname>Khashab</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Valeshabad</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>W</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Multicenter experience with performance of ERCP in patients with an indwelling duodenal stent</article-title>. <source>Endoscopy</source>
<year>2014</year>; <volume>46</volume>: <fpage>252</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="pmid">24500975</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270024-cit-0020">
<string-name>
<surname>Simoes</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Schattner</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Gerdes</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic stenting for malignant biliary obstruction is technically successful in patients with preexisting duodenal stents</article-title>. <source>Endosc Int Open</source>
<year>2022</year>; <volume>10</volume>: <fpage>e429</fpage>&#x02013;<lpage>e433</lpage>.<pub-id pub-id-type="pmid">35433215</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270024-cit-0021">
<string-name>
<surname>Staub</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Siddiqui</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>LJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>ERCP performed through previously placed duodenal stents: A multicenter retrospective study of outcomes and adverse events</article-title>. <source>Gastrointest Endosc</source>
<year>2018</year>; <volume>87</volume>: <fpage>1499</fpage>&#x02013;<lpage>1504</lpage>.<pub-id pub-id-type="pmid">29425886</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270024-cit-0022">
<string-name>
<surname>Yamao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kitano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takenaka</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: A multicenter cohort study in West Japan</article-title>. <source>Gastrointest Endosc</source>
<year>2018</year>; <volume>88</volume>: <fpage>66</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">29382465</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270024-cit-0023">
<string-name>
<surname>Debourdeau</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Caillol</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zemmour</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic management of concomitant biliary and duodenal malignant obstruction: Impact of the timing of drainage for one vs. two procedures and the modalities of biliary drainage</article-title>. <source>Endosc Ultrasound</source>
<year>2021</year>; <volume>10</volume>: <fpage>124</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">33818527</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270024-cit-0024">
<string-name>
<surname>Canakis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hathorn</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Irani</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Baron</surname>
<given-names>TH</given-names>
</string-name>. <article-title>Single session endoscopic ultrasound&#x02010;guided double bypass (hepaticogastrostomy and gastrojejunostomy) for concomitant duodenal and biliary obstruction: A case series</article-title>. <source>J Hepatobiliary Pancreat Sci</source>
<year>2022</year>; <volume>29</volume>: <fpage>941</fpage>&#x02013;<lpage>949</lpage>.<pub-id pub-id-type="pmid">34619022</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270024-cit-0025">
<string-name>
<surname>Geyl</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Redelsperger</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Yzet</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Risk factors for stent dysfunction during long&#x02010;term follow&#x02010;up after EUS&#x02010;guided biliary drainage using lumen&#x02010;apposing metal stents: A prospective study</article-title>. <source>Endosc Ultrasound</source>
<year>2023</year>; <volume>12</volume>: <fpage>237</fpage>&#x02013;<lpage>244</lpage>.<pub-id pub-id-type="pmid">36891940</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo270024-cit-0026">
<string-name>
<surname>Yamazaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic ultrasound&#x02010;guided hepaticogastrostomy versus choledochoduodenostomy for malignant biliary obstruction: A meta&#x02010;analysis</article-title>. <source>DEN Open</source>
<year>2023</year>; <volume>4</volume>: <elocation-id>e274</elocation-id>.<pub-id pub-id-type="pmid">37455944</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo270024-cit-0027">
<string-name>
<surname>Garcia&#x02010;Sumalla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Loras</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sanchiz</surname>
<given-names>V</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Multicenter study of lumen&#x02010;apposing metal stents with or without pigtail in endoscopic ultrasound&#x02010;guided biliary drainage for malignant obstruction&#x02010;BAMPI TRIAL: An open&#x02010;label, randomized controlled trial protocol</article-title>. <source>Trials</source>
<year>2022</year>; <volume>23</volume>: <fpage>181</fpage>.<pub-id pub-id-type="pmid">35216619</pub-id>
</mixed-citation></ref><ref id="deo270024-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="deo270024-cit-0028">
<string-name>
<surname>Balzano</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zerbi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Capretti</surname>
<given-names>G</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy</article-title>. <source>Br J Surg</source>
<year>2008</year>; <volume>95</volume>: <fpage>357</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">17933001</pub-id>
</mixed-citation></ref></ref-list></back></article>